Irish company Deciphex, specializing in AI-enhanced digital pathology, has succeeded in attracting €15M from Claret Capital Partners, bolstering its financial capacity for strategic growth. Deciphex aims to solidify its presence in the United States and become the premier provider of histopathology reporting services in the UK by 2027. The company’s platforms, Diagnexia and Patholytix, are designed to cater to clinical diagnostics and pharmaceutical research, respectively, illustrating a comprehensive approach to healthcare challenges.
How does Claret Capital’s involvement impact Deciphex’s growth?
Claret Capital Partners, Europe’s largest independent growth debt fund manager, has supported Deciphex by providing substantial funding since partnering with them in 2023. Historically, Claret has funded more than 190 small to medium enterprises across various technology sectors. Their continued financial backing underscores strong confidence in Deciphex’s innovative solutions and is intended to substantially enhance Deciphex’s market share.
“We’re delighted to be supporting Deciphex with this follow-on funding,” said Joey Mason, Venture Partner at Claret Capital Partners, acknowledging the strong execution abilities demonstrated by Deciphex in meeting market demands.
Can Deciphex’s technology alleviate global healthcare challenges?
Deciphex’s mission focuses on tackling global shortages of pathologists by automating repetitive tasks and enhancing diagnostic accuracy and speed through AI-driven digital pathology. More than 70% of healthcare decisions depend on such tests, but healthcare systems worldwide are experiencing severe backlogs due to increasing patient demands. The company’s Diagnexia platform is poised to reduce diagnostic backlogs through a network of global subspecialists, while Patholytix aims to streamline drug development through improved preclinical safety assessments.
“This extended relationship with Claret Capital Partners provides us with the capital to execute on our most ambitious growth plans,” stated Donal O’Shea, Founder and CEO of Deciphex.
In previous financial developments, Deciphex raised €31M in a Series C funding round led by Molten Ventures in early 2025. This allowed the company to significantly boost its operational capabilities and expand its geographical reach, reinforcing its presence in lucrative markets such as the United States, United Kingdom, European Union, Canada, and Japan.
Deciphex, founded in 2017, harnesses AI technology with the aim of transforming diagnostic workflows and speeding up pathology processes. By facilitating faster and reliable diagnoses, Deciphex enables pathologists to focus on intricate cases, providing a significant advantage in reducing workflow stress and improving patient outcomes. Additionally, their platforms are depicted to improve efficiency by up to 40% without compromising on accuracy.
Operating with an employee base of 223 across various international locations, Deciphex is strategically leveraging its platforms to manage around 97,000 cases annually through a vast network of 250+ subspecialty pathologists. The strategic objective remains to upscale these operations while maintaining shareholder interest.
This financial endorsement from Claret Capital Partners represents a strategic enhancement for Deciphex, enabling advancements in AI-powered pathology and facilitating its expansion in key markets. The outcome-oriented approach of Deciphex addresses essential healthcare challenges by improving diagnostic accuracy and operational efficiency. Continuous investment in technology and strategic partnerships are vital for addressing workforce shortages in the healthcare sector, while optimizing technology’s role in patient care.
